Fibrosis-4 Score (FIB-4) screening in patients with diabetes mellitus by a retrospective analysis of HbA1c laboratory requisitions

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032154

Enrollment

750000

Registered

2023-06-29

Start date

2023-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11

Interventions

Group 1: Retrospective identifican of HbA1c laboratory requistions of the year 2022 with available concomitant results for ALT, AST, and platelets, so that the FIB-4 score can be calculated

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: HbA1c values ALT, AST, platelets Age Sex

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Estimation of the prevalence of the three FIB-4 risk categories in patients with HbA1c > 6.5% stratified by sex and age	—

Secondary

Measure	Time frame
Comparison of patients with HbA1c > 6.5% vs. 6.5%, comparision between individuals with and without available FIB-4 score, stratified to sex and age. Estimation of the relevance of the HbA1c value on the FIB-4 category stratified by age and sex.	—

Countries

Germany

Contacts

Public ContactJohannes Wiegand

Universität Leipzig, Bereich Hepatologie

johannes.wiegand@medizin.uni-leipzig.de+493419712330

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026